Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMedOpen access

The use of stem cells in ischemic heart disease treatment.

Litwinowicz R., Kapelak B., Sadowski J., Kędziora A., Bartus K.

Narrative Review on Cardiovascular Disease, published in Kardiochir Torakochirurgia Pol (2018) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Kardiochir Torakochirurgia Pol (2018)
Country
Poland
Reported sample size
—
Source database
PubMed
PMID
30310400
PMCID
PMC6180025
DOI
10.5114/kitp.2018.78446
Citations
14

Abstract (original English)

Ischemic heart disease is a major cause of death and disabilities worldwide. Unfortunately, not all patients are suitable for direct revascularization. Cell-based therapies may be alternative options because of their potential to promote neovascularisation and endothelial repair, improving myocardial perfusion. The success of cell-based therapies depends on the type of implanted stem cells, delivery method and underlying disease. Several different cell populations including bone marrow-derived mononuclear cells (MNCs), mesenchymal stromal cells (MSCs), CD34+, CD133+, endothelial progenitor cells, adipose-derived mesenchymal stromal cells (ASCs) and stem cells from placenta and umbilical cord have been investigated. Presently, no consensus exists about the best cell type for clinical regenerative therapy. Because the system of coronary arteries in the ischemic area is poor and most of the coronary artery is significantly narrowed or closed, direct implantation of stem cells in the ischemic area of the heart muscle appears an attractive method. Choroba niedokrwienna serca jest główną przyczyną zgonu i niepełnosprawności na świecie. Nie wszyscy pacjenci mogą jednak być zakwalifikowani do bezpośrednich metod rewaskularyzacji. Alternatywą są terapie oparte na wykorzystaniu komórek macierzystych ze względu na ich potencjał do odbudowy łożyska naczyniowego oraz poprawy perfuzji mięśni

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research